Your browser doesn't support javascript.
loading
A systematic review and meta-analyses on the prevalence of pregnancy outcomes in migraine treated patients: a contribution from the IMI2 ConcePTION project.
Dudman, Daniel C; Tauqeer, Fatima; Kaur, Moninder; Ritchey, Mary E; Li, Hu; Lopez-Leon, Sandra.
Afiliación
  • Dudman DC; Novartis Pharmaceuticals Corporation, One Health Plaza, Building 339-1131, East Hanover, NJ, 07936-1080, USA.
  • Tauqeer F; Center for Pharmacoepidemiology and Treatment Science, Rutgers University, New Brunswick, NJ, USA.
  • Kaur M; Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, 08854, USA.
  • Ritchey ME; PharmacoEpidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo, Oslo, Norway.
  • Li H; PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Blindern, Postbox 1068, 0316, Oslo, Norway.
  • Lopez-Leon S; Former Cognizant Technology Solutions, 1 Kingdom Street, London, W2 6BD, UK.
J Neurol ; 269(2): 742-749, 2022 Feb.
Article en En | MEDLINE | ID: mdl-33792783
The present study aims to summarize the safety profile of the medications used to treat migraine during pregnancy by performing a systematic review and meta-analyses. The term "migrain*" combined with pregnancy terms were used to search Embase, PubMed, PsychInfo, Scopus, and Web of Science through 31 December 2020. Pooled prevalences of untreated and treated migraine patients were estimated using MetaXL software. Pooled odds ratios (OR) using random effects models were estimated in RevMan 5. All the identified studies assessed medications used to treat acute migraine. The pooled prevalence of adverse pregnancy outcomes in patients prescribed any migraine medication ranged from 0.4% (95% CI 0.2-0.7%) for stillbirth to 12.0% (95%CI 7.8-16.9%) for spontaneous abortions. Among untreated patients with migraine, the pooled prevalence of the assessed pregnancy outcomes ranged from 0.6% (95% CI: 0-1.7%) for stillbirth to 10.4% (95% CI: 8.9-12%) for gestational age < 37 weeks. Given the limited data, it was only possible to perform OR meta-analyses for triptans. The adjusted ORs for triptan users compared the general population were: for major malformations 1.07 (95%CI: 0.83-1.39, p = 0.60); birth weight < 2500g 1.18 (95%CI: 0.94-1.48, p = 0.16); gestational age < 37 weeks 1.49 (95% CI: 0.37-6.08, p = 0.58). In conclusion, triptans do not appear to increase the risk of pregnancy outcomes when compared to the general population. It was not possible to assess other migraine medications. Further studies are needed to investigate the safety of individual medications of acute and prophylactic migraine treatment among pregnant women.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Aborto Espontáneo / Trastornos Migrañosos Tipo de estudio: Prevalence_studies / Risk_factors_studies / Systematic_reviews Límite: Female / Humans / Infant / Pregnancy Idioma: En Revista: J Neurol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Aborto Espontáneo / Trastornos Migrañosos Tipo de estudio: Prevalence_studies / Risk_factors_studies / Systematic_reviews Límite: Female / Humans / Infant / Pregnancy Idioma: En Revista: J Neurol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Alemania